Shuttle Pharmaceuticals Holdings, Inc.
SHPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.00 | -5.99 | -3.73 | -2,378.38 |
| FCF Yield | -3.30% | -0.39% | -0.07% | -0.00% |
| EV / EBITDA | -28.41 | -362.35 | -937.60 | -100,490.29 |
| Quality | ||||
| ROIC | -403.38% | -106.02% | -27.82% | 268.46% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.80 | 0.85 | 0.53 | 0.26 |
| Growth | ||||
| Revenue 3-Year CAGR | – | – | – | -100.00% |
| Free Cash Flow Growth | -30.84% | -110.03% | -787.81% | -697.73% |
| Safety | ||||
| Net Debt / EBITDA | 0.10 | 0.37 | 1.78 | -0.46 |
| Interest Coverage | -5.66 | -2.27 | -3.50 | -34.32 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | -7,899.27 | -4,969.82 |